New hepatitis b cocktail shows promise in Mid-Stage trial
Disease control
Completed
This study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely clear the hepatitis B virus from the blood. 244 adults with chronic hepatitis B who were already on antiviral therapy took part. The …
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC